MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With …
NASDAQ MediciNova will use the net proceeds from any sales of its stock to advance MediciNova's development activities for its lead programs, MN-221 (bedoradrine sulfate) in development for the treatment of acute asthma and chronic obstructive pulmonary … |
View full post on asthma – Google News